Multiple drug resistance and intermediate filaments

Cancer and Metastasis Reviews

Volumn 15, Issue 4, 1996, Pages 499-506

  Cress, Anne E ^a   Dalton, William S ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

cancer treatment; cytokeratin; cytoskeleton; intermediate filaments; multiple drug resistance

Indexed keywords

BLEOMYCIN; CISPLATIN; CYTOKERATIN; DOXORUBICIN; MELPHALAN; MITOMYCIN C; MITOXANTRONE;

CANCER CHEMOTHERAPY; CYTOSKELETON; HUMAN; INTERMEDIATE FILAMENT; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG RESISTANCE, MULTIPLE; HUMANS; INTERMEDIATE FILAMENTS; NEOPLASMS;

EID: 0030471641     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00054015     Document Type: Review

References (32)

1. Hedley DW: Flow cytometric assays of anticancer drug resistance (review). Ann NY Acad Sci 67: 341-353, 1993
2. Tattersall MH: Mechanisms of treatment failure. Recent results Cane Res 127: 43-47, 1993
3. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR et al., e. Dose and dose intensity of adjuvant chemotherapy for stage II. node-positive breast carcinoma. N Engl J Med 330: 1253-1259, 1994
4. Clynes M: Cellular models for multiple drug resistance in cancer (review). In vitro cell. Dev Biol 29A (Part 1): 171-179, 1993
5. Deffie AM, Alam T, Senevirante C, Beenken S, Batra JK, Shea TC, Henner WD, Goldenberg GJ: Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and resistant p388 leukemia. Cancer Res 48: 3595-3602, 1988
6. Simon S, Roy D, Schindler M: Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci USA 91: 1128-1132, 1994
7. Dulhanty AM, Li M, Whitmore GF: Isolation of Chinese hamster ovary cell mutants deficient in excision repair and mitomycin C bioactivation. Cancer Res 49: 117-122, 1989
8. Dalton WS, Cress AE, Alberts DS, Trent JM: Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res 48: 1882-1888, 1988
9. Moll R: Molecular diversity of cytokeratins: significance for cell and tumor differentiation. Acta Histochem - Suppl 41: 117-127, 1991
10. Durr FE: Biologic and biochemical effects of mitoxantrone. Sem Oncol 11: 3-10, 1984
11. Dorr RT, Fritz WL: Cancer Chemotherapy Handbook, p. 785. New York: Elsevier Science Publishing Co., Inc., 1983
12. Gabor F, Wollman K, Theyer G, Haberl I, Hamilton C: In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells. Anti-cancer Res 14: 1943-1950, 1994
13. Haskell CM, Sullivan A: Comparative survival in tissue culture of normal and neoplastic human cells exposed to adriamycin. Cancer Res 34: 2991-2994, 1974
14. Scott CA, Westmacott D, Broadhurst MJ, Thomas GJ, Hall MJ: 9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures. Brit J Cancer 53: 595-600, 1986
15. Durr FE: Biologic and biochemical effects of mitoxantrone. Sem Oncol 11: 3-10, 1984
16. Cress AE: Modification of keratin by the chemotherapeutic drug mitoxantrone. Biochem Pharm 37: 3043-3046, 1988
17. Bauman PA: Interactions of mitoxantrone with cytokeratin in human and murine tumor cells: University of Arizona, 1993
18. Marchuk D, McCrohon, Fuchs E: Remarkable conservation of structure among intermediate filament genes. Cell 39: 491-498, 1984
19. Steinert PM: Structure, function and dynamics of keratin intermediate filaments (review). J Invest Dermatol 100: 729-734, 1993
20. Coulombe PA: The cellular and molecular biology of keratins: beginning a new era. Curr Opin Cell Biol 5: 17-29, 1993
21. Klymkowsky MW, Bachant JB, Domingo A: Cell Motil. Cytoskel 14: 309-311, 1989
22. Nagle RB: Cytokeratin expression in carcinoma. Vol 2, p 387-410: Academic Press, 1994
23. Bodenmuller H, Ofenloch-Hahnle B, Lane EB, Dessauer A, Bottger V, Donie F: Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay. Enzymun-Test CYFRA 21-1, Internal J Biol Markers 9: 75-81, 1994
24. Bynum WF, Contagion, 1st edition, p 494. Princeton: Princeton University Press, 1981
25. Bauman PA, Dalton WS, Anderson JM, Cress AE: Expression uf cytokeratin confers multiple drug resistance. Proc Nat Acad Sci USA 91: 5311-5314, 1994
26. Anderson JM, Heindl LM, Bauman PA, Ludi CW, Dalton WS, Cress AE: Cytokeratin expression results in a drug-resistant phenotype to six different chemotherapeutic agents. Clin Cancer Res 2: 97-105, 1996
27. Brambilla E, Moro D, Gazzeri S, Brichon PY, Nagy-Mignotte H, Morel F, Jacrot M, Brambilla C: Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma. J Clin Oncol 9: 50-61, 1991
28. Oshima RG: Intermediate filament molecular biology. Curr Opin Cell Biol 4: 110-116, 1992
29. Lu X, Lane EB: Retrovirus-mediated transgenic keratin expression in cultured fibroblasts: specific domain functions in keratin stabilization and filament formation. Cell 62: 681-696, 1990
30. Kulesh DA, Cecena G, Darmon YM, Vasseur M, Oshima RG: Post-translational regulation of keratins: degradation of mouse and human keratins 18 and 8. Mol Cell Biol 9: 1553-1565, 1989
31. Nickoloff BJ, Turka LA: Keratinocytes: key immunocytes of the integument. Amer J Pathol 143: 325-331, 1993
32. Haskell CM, Sullivan A: Comparative survival in tissue culture of normal and neoplastic human cells exposed to adriamycin. Cancer Res 34: 2991-2994, 1974